Research Australia is proud to be joining Australian Clinical Trials Alliances (ACTA) to bring together the Clinical Trials 2017: National Tribute & Awards Ceremony.
This partnership is in line with Research Australia’s collaborative strategy that continues to work towards an improved clinical trials environment driving evidence-based change in the health system and new commercial opportunities.
Hon Greg Hunt MP, Minister for Health and Minister for Sport, will attend the Clinical Trials 2017: National Tribute and Awards Ceremony to present the prestigious ACTA Trial of the Year Award and the inaugural ACTA STInG Excellence in Trial Statistics Award.
Continue reading “Clinical Trials 2017: National Tribute & Awards Ceremony”
Research Australia has made a submission to the Senate Select Committee Inquiry into Funding for Research into Cancers with Low Survival Rates. Many of the Terms of Reference have relevance beyond brain cancers, cancers with low survival rates and low incidence cancers; our submission approaches the Inquiry from this broader perspective.
Government funding available for health and medical research is finite. While cancers with low survival rates are undoubtedly worthy of more funding, any increase in funding for one area has implications for the funding available to other disease areas. Improvements in survival are related to global research rather than specifically to the volume or subject of Australian research, and it is important that Australian researchers and patients have access to, and contribute to this global effort. This is particularly relevant for low incidence cancers and other rare diseases, because the number of patients in Australia is likely to be low and appropriate research collaborators are in many cases likely to be based overseas. Thus, when allocating funding we also need to consider the level of funding available and the research activity undertaken globally.
Research Australia also suggests there is merit in looking at approaches taken by other countries. This includes strategies such as rare disease policies that have been established in more than 20 countries as a means of providing a policy framework for a considered and comprehensive approach to the provision of research, diagnosis and access to treatment for rare diseases. In an area where the only available therapies are often experimental, a single policy that brings research, diagnosis and treatment together is valuable.
Read the full Research Australia Submission Cancers with Low Survival Rates today.
Yesterday the Australian government launched the National Science Statement, outlining its commitment to science as part of the National Innovation and Science Agenda.
This comes in advance of the 2030 Strategic Plan for Innovation, Science and Research, with Innovation and Science Australia commissioned by the government to review Australia’s performance in science and innovation, and develop a plan through to 2030.
Research Australia welcomes the Statement’s long-term approach to science in Australia; in particular, the explicit references to secure and sustainable investment and recognition of the role of research as a central contributor to GDP. Continue reading “National Science Statement”
CRCs have played a key role in the translation of Australian health and medical research. Research Australia’s response to the Government’s consultation on Themes and Priorities for the CRC Programme took the opportunity to advocate for the reinstatement of Public Good CRCs, which are specifically excluded by the most recent Guidelines for the CRC Programme.
Research Australia’s Submission – CRC Themes Consultation
30 January 2017
Australia’s peak body for health and medical research has welcomed the appointment of the
Hon Brad Hazzard MP as Minister for Health and Minister for Medical Research.
“Bringing health and medical research back under one senior minister presents new opportunities to better integrate health and medical research with clinical care. This will mean better outcomes for patients and opportunities to achieve sustainable spending within the NSW health budget,” Research Australia CEO Nadia Levin said. Continue reading “Health and medical researchers welcome appointment of Hon Brad Hazzard MP to Health portfolio”
Congratulations to the 2017 Australian of the Year recipient Emeritus Professor Alan Mackay-Sim. Research Australia is thrilled that a medical researcher has been chosen for this honour.
Professor Mackay-Sim has spent over 20 years making discoveries on the human sense of smell and the biology of nasal cells. He and his team proved it was safe to transplant nasal cells to the spinal cord.
In Prof Mackay-Sim’s acceptance speech, he highlighted the importance of investing in research for the future. Continue reading “Medical Researcher becomes Australian of the Year”
In its pre-Budget submission to the Treasurer, Research Australia has urged the Government to remain committed to the full implementation of the National Innovation and Science Agenda, continue funding of the MRFF’s capital in accordance with the existing timetable, and emphasised the need to at least maintain real levels of funding for the NHMRC and ARC grant programs.
The submission also raises the looming issue of the funding of indirect research costs associated with MRFF grants. Research Australia has called for MRFF grants to be included as Category 1 income for universities’ Research Block Grants and for their inclusion in the IRIISS scheme for MRIs in the short term, and echoes the MRFF Advisory Board’s call for a whole of government approach to this issue in the longer term.
Pre Budget Submission
The Biomedical Translation Fund (BTF) is to be funded with $250 million over financial years 2015/16 and 2016/17, diverted from contributions originally earmarked for the MRFF.
The BTF will use existing commercial Fund Managers for co-investment on a 50/50 basis, with the investment managers to source the other co-investors. Continue reading “$500 million fund will help build Australia’s biomedical industry of the future”